Home/Filings/4/0000950170-25-030032
4//SEC Filing

Prior Stephen David 4

Accession 0000950170-25-030032

CIK 0001880438other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 4:19 PM ET

Size

7.5 KB

Accession

0000950170-25-030032

Insider Transaction Report

Form 4
Period: 2025-02-26
Prior Stephen David
Chief Strategy Officer
Transactions
  • Award

    Common Stock

    2025-02-26+28,00061,313 total
  • Award

    Stock Option (right to buy)

    2025-02-26+56,00056,000 total
    Exercise: $1.13Exp: 2035-02-25Common Stock (56,000 underlying)
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
  • [F2]Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
  • [F3]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.

Documents

1 file

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0002042268

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 4:19 PM ET
Size
7.5 KB